Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-15, Stock:NVO, The news for the past five days is as follows:
2018-08-08: NEWS1: Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates.NEWS2: Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates.NEWS3: Amazon, Novo Nordisk and Tesla are the Yahoo Finance charts of the day..NEWS4: Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates.NEWS5: [$$] European Corporate Roundup for Wednesday.NEWS6: Novo Nordisk: 2Q Earnings Snapshot.NEWS7: Novo Nordisk CEO Sees Demand for Better Products.NEWS8: Novo Nordisk CEO Sees Demand for Better Products.NEWS9: [$$] Shares in Novo Nordisk fall after warning on US price cuts.NEWS10: Novo Nordisk H1 Profit Rises; Affirms FY18 Outlook - Quick Facts.NEWS11: Novo Nordisk H1 Profit Rises; Affirms FY18 Outlook - Quick Facts.
2018-08-09: nan
2018-08-10: NEWS1: Novo Nordisk (NVO) Q2 2018 Earnings Conference Call Transcript.NEWS2: Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus.NEWS3: Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus.NEWS4: Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN&apos;s Pipeline Updates in Focus.NEWS5: Eli Lilly Stock History.
2018-08-13: NEWS1: Novo Nordisk’s Long-Acting Insulins: A Performance Overview.NEWS2: Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?.NEWS3: Novo Nordisk: A Financial Overview after the First Half of 2018.NEWS4: The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers.NEWS5: The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers.NEWS6: The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers.
2018-08-14: NEWS1: Novo Nordisk's Pricing Pressures Aren't Going Away.NEWS2: Novo Nordisk's Pricing Pressures Aren't Going Away.NEWS3: Novo Nordisk&apos;s Pricing Pressures Aren&apos;t Going Away.NEWS4: European ADRs Move Higher in Tuesday Trading.NEWS5: European ADRs Move Higher in Tuesday Trading.NEWS6: A Look at Novo Nordisk’s Human Insulin and Obesity Business.NEWS7: How Novo Nordisk’s Premix Insulin Is Positioned after H1 2018.NEWS8: What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2.NEWS9: Novo Nordisk’s Fast-Acting Insulins: A Performance Overview.

Answer: Decrease